CRISPR Therapeutics AG (CRSP) vs Dianthus Therapeutics, Inc. (DNTH)
A side-by-side comparison of CRISPR Therapeutics AG and Dianthus Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRSP
CRISPR Therapeutics AG
$54.44HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
DNTH
Dianthus Therapeutics, Inc.
$84.57HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Total return — CRSP vs DNTH
growth of $100 · dividends reinvested · last 8yCRSP -12.0% (-1.6%/yr)DNTH -62.1% (-11.4%/yr)CRSP compounded faster over this window
CRSP DNTH
CRSP vs DNTH: by the numbers
- •CRSP is the larger company ($5.25B vs $4.73B market cap).
- •Both run net losses; DNTH's is the smaller (-1570.85% vs -3368.72% net margin).
Metrics side by side
Valuation
| Metric | CRSP | DNTH |
|---|---|---|
| P/S ratio | 392.08 | 2484.51 |
| P/B ratio | 3.01 | 4.04 |
Profitability
| Metric | CRSP | DNTH |
|---|---|---|
| Gross margin | -6537.01% | 96.01% |
| Operating margin | -16191.40% | -8739.34% |
| Net margin | -3368.72% | -1570.85% |
| ROE | -25.83% | -2.55% |
| ROIC | -21.12% | -18.48% |
Growth (annualized)
| Metric | CRSP | DNTH |
|---|---|---|
| Revenue CAGR (5Y) | 37.32% | N/A |
| Total return CAGR (5Y) | -10.97% | -5.50% |
Frequently asked
- How have CRSP and DNTH total returns compared?
- Over the past 5 years, CRSP delivered -10.97% and DNTH delivered -5.50% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
CRISPR Therapeutics AG ROEDianthus Therapeutics ROECRISPR Therapeutics AG operating marginDianthus Therapeutics operating marginCRISPR Therapeutics AG revenue growthDianthus Therapeutics revenue growthCRISPR Therapeutics AG free cash flowDianthus Therapeutics free cash flow
CRISPR Therapeutics AG & Dianthus Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.